INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Ciongoli Gregory Austin reported GOSS

Director · Gossamer Bio, Inc. · Gossamer Bio, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
30.0K
Price
—
Executed
Sep 23, 2026
Disclosed
Sep 25, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 23 executedSep 25, 2026 disclosed

GOSS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GOSS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DO
    Daniel Thomas ODirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CJ
    Cox Russell J.Director
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Drynan SkyeDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ND
    Nathan Steven DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MS
    Milligan SandraDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    QD
    Quisel John DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GB
    Giraudo BryanCOO/CFO
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GB
    Giraudo BryanCOO/CFO
    GOSSGossamer Bio, Inc.
    Grant or award
    		A$25K
    25 sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SP
    Smith Robert Paul JRChief Commercial Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PC
    Peterson CarynChief Development Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Drynan SkyeDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    ND
    Nathan Steven DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MS
    Milligan SandraDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SP
    Smith Robert Paul JRChief Commercial Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    572.0K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    562.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SP
    Smith Robert Paul JRChief Commercial Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    562.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    9,167 sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    40.0K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PC
    Peterson CarynEVP, Regulatory Affairs
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    18.8K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    162.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-063616
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 23, 2026
    Published
    Sep 25, 2026
    Ingested by INSIDER
    Nov 5, 02:15 UTC
    Last re-read
    Nov 5, 02:15 UTC

    Extracted facts

    Filer
    Ciongoli Gregory Austin
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Gossamer Bio, Inc. — Stock Option (Right to Buy)
    Ticker
    GOSS
    Shares
    30.0K
    Price per share
    $0
    Execution date (reported)
    Sep 23, 2026
    Owned after transaction
    30.0K shares
    Days from execution to publication
    2

    What this establishes

    Ciongoli Gregory Austin filed this Form 4 reporting a grant or award of GOSS on Sep 23, 2026. It became public on Sep 25, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Ciongoli Gregory Austincik:0002023732
    Issuer
    Gossamer Bio, Inc.cik:0001728117

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.